Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
June 25, 2020 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J, June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC)...